Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014

Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

In this issue of the Journal of Clinical Investigation, Marjolein van Egmond and colleagues at the VU University Medical Center found that macrophage populations mediate tumor cell removal following monoclonal antibody treatment by actively phagocytosing tumor cells. Macrophage-dependent tumor cell removal required both the high affinity and low affinity Fc receptors.

This study suggests that monoclonal antibody therapies that are optimized to enhance macrophage recruitment and activity may enhance removal of circulating in cancer patients.

Explore further: Monoclonal antibody targets, kills leukemia cells

More information: Macrophages eliminate circulating tumor cells after monoclonal antibody therapy, J Clin Invest. DOI: 10.1172/JCI66776

Related Stories

Monoclonal antibody targets, kills leukemia cells

March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Engineered anti-toxin antibodies improve efficacy

January 9, 2014
The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent studies suggest that the constant region (Fc) of ...

Monoclonal antibodies show promise as effective HIV therapy

October 30, 2013
A research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has demonstrated that a group of recently discovered antibodies may be a highly effective therapy for the treatment of HIV. Published on-line ...

Bright future ahead for antibody cancer therapy

March 15, 2012
Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center

Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma

April 19, 2013
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

Inhibiting macrophage MerTK signaling creates an innate immune response against cancer

July 8, 2013
The tyrosine kinase MerTK plays a prominent role in the body's immune response. MerTK signaling helps "calm" the body's first line of immunity, the macrophage, while it performs the routine duties - clearing cells that die ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.